These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 37268281)

  • 1. Atrioventricular Nodal Ablation Is Not an Effective Treatment Strategy in Catecholaminergic Polymorphic Ventricular Tachycardia.
    Asaki SY; Kessler D; Nayak A; Kim JJ; Miyake CY
    Tex Heart Inst J; 2023 May; 50(3):. PubMed ID: 37268281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Catecholaminergic polymorphic ventricular tachycardia in children: analysis of therapeutic strategies and outcomes from an international multicenter registry.
    Roston TM; Vinocur JM; Maginot KR; Mohammed S; Salerno JC; Etheridge SP; Cohen M; Hamilton RM; Pflaumer A; Kanter RJ; Potts JE; LaPage MJ; Collins KK; Gebauer RA; Temple JD; Batra AS; Erickson C; Miszczak-Knecht M; Kubuš P; Bar-Cohen Y; Kantoch M; Thomas VC; Hessling G; Anderson C; Young ML; Cabrera Ortega M; Lau YR; Johnsrude CL; Fournier A; Kannankeril PJ; Sanatani S
    Circ Arrhythm Electrophysiol; 2015 Jun; 8(3):633-42. PubMed ID: 25713214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of defibrillator therapy in catecholaminergic polymorphic ventricular tachycardia.
    Roses-Noguer F; Jarman JW; Clague JR; Till J
    Heart Rhythm; 2014 Jan; 11(1):58-66. PubMed ID: 24120999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bilateral cardiac sympathetic denervation for refractory arrhythmia in an individual with catecholaminergic polymorphic ventricular tachycardia associated with T-cell-mediated ganglionitis.
    Carpenter A; Connolly GM; Duncan E; Nisbet A
    BMJ Case Rep; 2022 Feb; 15(2):. PubMed ID: 35165125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of implantable cardioverter defibrillators in young patients with catecholaminergic polymorphic ventricular tachycardia: success depends on substrate.
    Miyake CY; Webster G; Czosek RJ; Kantoch MJ; Dubin AM; Avasarala K; Atallah J
    Circ Arrhythm Electrophysiol; 2013 Jun; 6(3):579-87. PubMed ID: 23667268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Description of a novel RyR2 mutation in a juvenile patient with symptomatic catecholaminergic polymorphic ventricular tachycardia in sleep and during exercise: a case report.
    Seidlmayer LK; Riediger F; Pagonas N; Nordbeck P; Ritter O; Sasko B
    J Med Case Rep; 2018 Oct; 12(1):298. PubMed ID: 30296944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Left cardiac sympathetic denervation for catecholaminergic polymorphic ventricular tachycardia.
    Wilde AA; Bhuiyan ZA; Crotti L; Facchini M; De Ferrari GM; Paul T; Ferrandi C; Koolbergen DR; Odero A; Schwartz PJ
    N Engl J Med; 2008 May; 358(19):2024-9. PubMed ID: 18463378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flecainide Is Associated With a Lower Incidence of Arrhythmic Events in a Large Cohort of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia.
    Bergeman AT; Lieve KVV; Kallas D; Bos JM; Rosés I Noguer F; Denjoy I; Zorio E; Kammeraad JAE; Peltenburg PJ; Tobert K; Aiba T; Atallah J; Drago F; Batra AS; Brugada R; Borggrefe M; Clur SB; Cox MGPJ; Davis A; Dhillon S; Etheridge SP; Fischbach P; Franciosi S; Haugaa K; Horie M; Johnsrude C; Kane AM; Krause U; Kwok SY; LaPage MJ; Ohno S; Probst V; Roberts JD; Robyns T; Sacher F; Semsarian C; Skinner JR; Swan H; Tavacova T; Tisma-Dupanovic S; Tfelt-Hansen J; Yap SC; Kannankeril PJ; Leenhardt A; Till J; Sanatani S; Tanck MWT; Ackerman MJ; Wilde AAM; van der Werf C
    Circulation; 2023 Dec; 148(25):2029-2037. PubMed ID: 37886885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interventional electrophysiology and its role in the treatment of cardiac arrhythmia.
    Teo WS; Kam R; Tan A
    Ann Acad Med Singap; 1998 Mar; 27(2):248-54. PubMed ID: 9663319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiofrequency catheter ablation of the AV node to improve the function of an antitachycardia implantable defibrillator.
    Pitney MR; Davis MJ; May CD
    Pacing Clin Electrophysiol; 1992 Nov; 15(11 Pt 1):1657-60. PubMed ID: 1279531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Avoidance of electromagnetic interference to implantable cardiovertor-defibrillator during atrioventricular node ablation for atrial fibrillation using transvenous cryoablation.
    Siu CW; Tse HF; Lau CP
    Pacing Clin Electrophysiol; 2006 Aug; 29(8):914-6. PubMed ID: 16923011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of flecainide therapy on inappropriate shocks and arrhythmias in catecholaminergic polymorphic ventricular tachycardia.
    Jacquemart C; Ould Abderrahmane F; Massin MM
    J Electrocardiol; 2012; 45(6):736-8. PubMed ID: 22672791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of ivabradine to control ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia.
    Vaksmann G; Klug D
    Pacing Clin Electrophysiol; 2018 Oct; 41(10):1378-1380. PubMed ID: 29989676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in the diagnosis and treatment of catecholaminergic polymorphic ventricular tachycardia.
    Roston TM; Cunningham TC; Sanatani S
    Cardiol Young; 2017 Jan; 27(S1):S49-S56. PubMed ID: 28084961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flecainide therapy suppresses exercise-induced ventricular arrhythmias in patients with CASQ2-associated catecholaminergic polymorphic ventricular tachycardia.
    Khoury A; Marai I; Suleiman M; Blich M; Lorber A; Gepstein L; Boulos M
    Heart Rhythm; 2013 Nov; 10(11):1671-5. PubMed ID: 23954267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Automatic arrhythmia identification using analysis of the atrioventricular association. Application to a new generation of implantable defibrillators. Participating Centers of the Automatic Recognition of Arrhythmia Study Group.
    Nair M; Saoudi N; Kroiss D; Letac B
    Circulation; 1997 Feb; 95(4):967-73. PubMed ID: 9054759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and genetic profile of catecholaminergic polymorphic ventricular tachycardia in Hong Kong Chinese children.
    Yu TC; Liu AP; Lun KS; Chung BH; Yung TC
    Hong Kong Med J; 2016 Aug; 22(4):314-9. PubMed ID: 27256466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Flecainide in the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia: A Randomized Clinical Trial.
    Kannankeril PJ; Moore JP; Cerrone M; Priori SG; Kertesz NJ; Ro PS; Batra AS; Kaufman ES; Fairbrother DL; Saarel EV; Etheridge SP; Kanter RJ; Carboni MP; Dzurik MV; Fountain D; Chen H; Ely EW; Roden DM; Knollmann BC
    JAMA Cardiol; 2017 Jul; 2(7):759-766. PubMed ID: 28492868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Catecholaminergic Polymorphic Ventricular Tachycardia.
    Wall JJ; Iyer RV
    Pediatr Emerg Care; 2017 Jun; 33(6):427-431. PubMed ID: 28570361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complex atrial arrhythmias as first manifestation of catecholaminergic polymorphic ventricular tachycardia: an unusual course in a patient with a new mutation in ryanodine receptor type 2 gene.
    Lawrenz W; Krogmann ON; Wieczorek M
    Cardiol Young; 2014 Aug; 24(4):741-4. PubMed ID: 23985380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.